EXPRS2 — ExpreS2ion Biotech Holding AB Share News
0.000.00%
Last trade - 00:00- SEK24.46m
- -SEK8.46m
- SEK12.21m
Brief: Expres2ion: U.S. Patent Issue Notification For Glyco-Engineered Immunization Antigens
Brief: Expres2ion To Get Proceeds Of About SEK 60.1 Mln Through Completed Rights Issue
Brief: Expres2ion Biotech Q1 Operating Income Down At SEK 1.6 Mln
Brief: Expres2ion Announces A Rights Issue Of Units Of Approximately Sek 60 Million
Brief: Expres2ion Completes GLP Safety Study For ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate
Brief: Expres2ion's Associated Adaptvac Gets Payment After Bavarian's Phase Study
Brief: ExpreS2ion Biotech Q4 Operating Income SEK 2.284 Million
Brief: Expres2ion Gets Horizon Europe Grant Of EUR 8 Mln For Vaccine Development
Brief: ExpreS2ion Biotech Q3 EPS SEK -0.44
Brief: Expres2ion Biotech Exercises Warrants, Gets About SEK 3.4 Mln
Brief: Expres2ion Evaluates Strategic Options For Its Breast Cancer Vaccine Candidate
Brief: ExpreS2ion Biotech Q2 Operating Income at SEK 2.069 Million
Brief: Bavarian Nordic Phase 3 Study For COVID-19 Booster Vaccine Candidate Met Primary Objective
Brief: ExpreS2ion: 12-Month Durability Data Announced For Abncov2 Phase II Clinical Trial
Brief: Expres2ion Biotech Holding Q1 Operating Income Up At SEK 2.6 Mln
Brief: ExpreS2ion Biotech Q1 EPS at SEK -0.7
Brief: Expres2ion Says A Rights Issue Of Units Of Approximately SEK 102.4 Mln
Brief: ExpreS2ion Awarded Grant For Developing New Platforms For Universal Mucosal Vaccines
Brief: Expres2ion Q4 Loss After Financial Items Widens To SEK 53.3 Mln